click below
click below
Normal Size Small Size show me how
Other Blood Groups
| Question | Answer |
|---|---|
| What makes an antibody clinically significant? | It shortens RBC survival (HTR or HDFN). Usually IgG reacting at 37°C/AHG. |
| Stronger reaction with homozygous cells (double dose) than heterozygous cells (single dose). | Dosage |
| Which systems show dosage? | Kidd, Duffy, Rh (not D), MNSs. "Kidd and Duffy the Monkey eat M&Ms." |
| Which antigens are ENHANCED by enzymes? | Kidd, Rh, Lewis, I, P. |
| Which antigens are DESTROYED by enzymes? | Duffy (Fya, Fyb), M, N, S, s. |
| How do Kell antigens respond to enzymes and what destroys them? | Unaffected by enzymes; destroyed by DTT, AET, ZZAP. |
| Cold antibody mnemonic | LIiPMABHN (Lewis, I/i, P1, M, A/B/H, N). |
| Cold antibody traits? | IgM, RT or colder, no HTR/HDFN. |
| Warm antibodies traits? | IgG at 37°C/AHG; cause HTR and HDFN. |
| Warm antibodies list? | Rh, Kidd, Kell, Duffy, S, s, U. |
| Donor selection for a clinically insignificant cold antibody? | No antigen typing needed; crossmatch compatible. |
| Donor selection for a clinically significant warm antibody? | Antigen-negative units AND compatible crossmatch. |
| What does phenotype Jk(a+b+) mean? | Has both Jka and Jkb; heterozygous (JkaJkb); weaker dosage reactions. |
| Which glycophorin carries M and N? S, s, U? | GPA = M, N. GPB = S, s, U. Genes on chromosome 4. |
| Amino acids defining M vs N? | M: Ser1/Gly5. N: Leu1/Glu5. |
| Amino acid defining S vs s? | S: Met29. s: Thr29 (on GPB). |
| What is U antigen and who lacks it? | High-incidence (~99.9%), present when S or s is; U-negative is rare, mostly Black patients; anti-U is IgG, significant. |
| Characteristics of anti-M and anti-N? | IgM, cold, usually insignificant, destroyed by enzymes, show dosage. Treat as significant if reactive at 37°C/AHG. |
| Characteristics of anti-S and anti-s? | IgG, AHG, significant (HTR/HDFN), dosage, enzyme-destroyed. |
| Kidd protein function and null test? | Urea transporter; Jk(a-b-) RBCs resist lysis in 2M urea. |
| What is Jk3? | High-incidence antigen on all Jk(a+) or Jk(b+) cells. |
| Why do Kidd antibodies cause delayed HTR? | Titer falls undetectable, then re-exposure triggers anamnestic IgG in 3-10 days; extravascular hemolysis; pre-screen may be negative. |
| Characteristics of anti-Jka/anti-Jkb? | IgG, 37°C/AHG, dosage, enzyme-enhanced, often complement-binding. |
| Why is Fy(a-b-) protective? | Lacks DARC receptor, so P. vivax (and knowlesi) cannot invade RBCs. |
| Frequency of Fy(a-b-)? | ~68% of Black Americans; ~100% West Africa; rare in Whites. |
| Characteristics of anti-Fya/anti-Fyb? | IgG, 37°C/AHG, acute + delayed HTR, HDFN, dosage; no reaction with enzyme-treated cells. |
| Duffy phenotype frequencies in Whites? | Fy(a+b-) 17%, Fy(a+b+) 49%, Fy(a-b+) 34%, Fy(a-b-) rare. |
| How immunogenic is Kell? | After ABO and D, K is the most immunogenic antigen. |
| Frequencies of K and k? | K ~9% (low incidence); k (Cellano) 99.8% (high incidence). |
| Characteristics and clinical significance of anti-K? | IgG/AHG; HTR and severe HDFN (suppresses erythropoiesis). |
| Kell genes and products? | KEL (chr 7) = Kell glycoprotein. XK (X chr) = Kx protein, the scaffold. |
| McLeod phenotype findings? | XK defect: no Kx, weak Kell, acanthocytes, neuromuscular disease, cardiomyopathy, CGD link. May make anti-Km/anti-Kx. |
| K0 (Kell null) phenotype? | KEL mutation; no Kell antigens; Kx present; normal RBCs, no disease; may make anti-Ku. |
| Kp and Js frequencies? | Kpa 2%, Kpb 99.9%. Jsa 20% Black / 0.1% White; Jsb high-incidence. |
| Lutheran carrier protein and agglutination pattern? | B-CAM (CD239); loose mixed-field agglutination. |
| Compare anti-Lua and anti-Lub. | Lua (8%): IgM, often naturally occurring, mild/none. Lub (99%): IgG, immune, mild-moderate HTR, mild HDFN. |
| Define HTLA antibodies. | High titer, low avidity; IgG at AHG; NOT significant; mask real antibodies (Knops, Chido/Rodgers). |
| Sda antigen and antibody features? | High incidence (~90%); refractile mixed-field clumps; not significant; neutralized by urine. |
| Anti-I vs anti-i disease associations? | Anti-I: Mycoplasma pneumoniae (cold agglutinin disease). Anti-i: infectious mononucleosis (EBV). |
| Anti-P disease association? | Paroxysmal cold hemoglobinuria (biphasic Donath-Landsteiner hemolysin). |